Jill S Barnholtz Sloan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/569964/publications.pdf

Version: 2024-02-01

428 papers 57,997 citations

83 h-index 224 g-index

452 all docs

452 docs citations

452 times ranked

59920 citing authors

#	Article	IF	Citations
1	CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010. Neuro-Oncology, 2013, 15, ii1-ii56.	0.6	5,799
2	The Somatic Genomic Landscape of Glioblastoma. Cell, 2013, 155, 462-477.	13.5	3,979
3	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. New England Journal of Medicine, 2015, 372, 2481-2498.	13.9	2,582
4	An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell, 2018, 173, 400-416.e11.	13.5	2,277
5	CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016. Neuro-Oncology, 2019, 21, v1-v100.	0.6	1,735
6	CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. Neuro-Oncology, 2015, 17, iv1-iv62.	0.6	1,727
7	Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell, 2016, 164, 550-563.	13.5	1,695
8	Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell, 2018, 173, 371-385.e18.	13.5	1,670
9	CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011–2015. Neuro-Oncology, 2018, 20, iv1-iv86.	0.6	1,624
10	The epidemiology of glioma in adults: a "state of the science" review. Neuro-Oncology, 2014, 16, 896-913.	0.6	1,586
11	Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. Journal of Clinical Oncology, 2004, 22, 2865-2872.	0.8	1,418
12	Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell, 2018, 173, 338-354.e15.	13.5	1,417
13	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet, The, 2020, 395, 1907-1918.	6.3	1,395
14	CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011. Neuro-Oncology, 2014, 16, iv1-iv63.	0.6	1,253
15	CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro-Oncology, 2017, 19, v1-v88.	0.6	1,236
16	CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013–2017. Neuro-Oncology, 2020, 22, iv1-iv96.	0.6	1,175
17	CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009–2013. Neuro-Oncology, 2016, 18, v1-v75.	0.6	995
18	Epidemiologic and Molecular Prognostic Review of Glioblastoma. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1985-1996.	1.1	933

#	Article	IF	Citations
19	CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014–2018. Neuro-Oncology, 2021, 23, iii1-iii105.	0.6	804
20	Brain tumor epidemiology: Consensus from the Brain Tumor Epidemiology Consortium. Cancer, 2008, 113, 1953-1968.	2.0	716
21	Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. Cell Reports, 2018, 23, 181-193.e7.	2.9	683
22	Predicting cancer outcomes from histology and genomics using convolutional networks. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E2970-E2979.	3.3	671
23	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro-Oncology, 2020, 22, 1073-1113.	0.6	543
24	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Reports, 2018, 23, 313-326.e5.	2.9	523
25	Alex's Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007–2011. Neuro-Oncology, 2015, 16, x1-x36.	0.6	414
26	Brain and other central nervous system tumor statistics, 2021. Ca-A Cancer Journal for Clinicians, 2021, 71, 381-406.	157.7	404
27	Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. Cancer Cell, 2018, 33, 721-735.e8.	7.7	396
28	An anatomic transcriptional atlas of human glioblastoma. Science, 2018, 360, 660-663.	6.0	384
29	Mechanisms and therapeutic implications of hypermutation in gliomas. Nature, 2020, 580, 517-523.	13.7	374
30	Adult Glioma Incidence and Survival by Race or Ethnicity in the United States From 2000 to 2014. JAMA Oncology, 2018, 4, 1254.	3.4	373
31	Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Research, 2015, 25, 316-327.	2.4	343
32	Proteogenomic and metabolomic characterization of human glioblastoma. Cancer Cell, 2021, 39, 509-528.e20.	7.7	327
33	Association of Maximal Extent of Resection of Contrast-Enhanced and Non–Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma. JAMA Oncology, 2020, 6, 495.	3.4	325
34	Longitudinal molecular trajectories of diffuse glioma in adults. Nature, 2019, 576, 112-120.	13.7	320
35	Epidemiology of Gliomas. Cancer Treatment and Research, 2015, 163, 1-14.	0.2	319
36	Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992-2006. Journal of the American Academy of Dermatology, 2011, 65, S17.e1-S17.e11.	0.6	309

#	Article	IF	Citations
37	Childhood Brain Tumor Epidemiology: A Brain Tumor Epidemiology Consortium Review. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2716-2736.	1.1	290
38	Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. Cell Systems, 2018, 6, 282-300.e2.	2.9	284
39	Targeting glioma stem cells through combined BMI1 and EZH2 inhibition. Nature Medicine, 2017, 23, 1352-1361.	15.2	279
40	Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors. Nature Genetics, 2017, 49, 789-794.	9.4	259
41	Incidence trends in primary malignant penile cancer. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 361-367.	0.8	256
42	Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Reports, 2018, 23, 194-212.e6.	2.9	245
43	Sex differences in GBM revealed by analysis of patient imaging, transcriptome, and survival data. Science Translational Medicine, $2019,11,.$	5.8	230
44	Development of a Panel of Genome-Wide Ancestry Informative Markers to Study Admixture Throughout the Americas. PLoS Genetics, 2012, 8, e1002554.	1.5	212
45	American Brain Tumor Association Adolescent and Young Adult Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. Neuro-Oncology, 2016, 18, i1-i50.	0.6	212
46	Prevalence and predictors of interval colorectal cancers in Medicare beneficiaries. Cancer, 2012, 118, 3044-3052.	2.0	207
47	Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. Cell Reports, 2018, 23, 255-269.e4.	2.9	204
48	Brain metastases: epidemiology. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 149, 27-42.	1.0	198
49	Burden of invasive squamous cell carcinoma of the penis in the United States, 1998-2003. Cancer, 2008, 113, 2883-2891.	2.0	196
50	Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. American Journal of Obstetrics and Gynecology, 2003, 189, 1120-1127.	0.7	179
51	Racial and ethnic variations in incidence and survivalÂof cutaneous melanoma in the United States, 1999-2006. Journal of the American Academy of Dermatology, 2011, 65, S26.e1-S26.e13.	0.6	179
52	Systematic Analysis of Splice-Site-Creating Mutations in Cancer. Cell Reports, 2018, 23, 270-281.e3.	2.9	177
53	Germline Mutations in Shelterin Complex Genes Are Associated With Familial Glioma. Journal of the National Cancer Institute, 2015, 107, 384.	3.0	172
54	Descriptive epidemiology of World Health Organization grades II and III intracranial meningiomas in the United States. Neuro-Oncology, 2015, 17, 1166-1173.	0.6	169

#	Article	IF	CITATIONS
55	The elderly left behind—changes in survival trends of primary central nervous system lymphoma over the past 4 decades. Neuro-Oncology, 2018, 20, 687-694.	0.6	159
56	Global incidence of malignant brain and other central nervous system tumors by histology, 2003–2007. Neuro-Oncology, 2017, 19, 1553-1564.	0.6	146
57	Incidence and Survival of Primary Dermatofibrosarcoma Protuberans in the United States. Dermatologic Surgery, 2016, 42, S24-S31.	0.4	139
58	A Distinct DNA Methylation Shift in a Subset of Glioma CpG Island Methylator Phenotypes during Tumor Recurrence. Cell Reports, 2018, 23, 637-651.	2.9	137
59	Epidemiology of Brain Tumors. Neurologic Clinics, 2018, 36, 395-419.	0.8	135
60	A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-Î ² Superfamily. Cell Systems, 2018, 7, 422-437.e7.	2.9	134
61	Descriptive epidemiology of pituitary tumors in the United States, 2004–2009. Journal of Neurosurgery, 2014, 121, 527-535.	0.9	130
62	Genetic Validation of the Protein Arginine Methyltransferase PRMT5 as a Candidate Therapeutic Target in Glioblastoma. Cancer Research, 2014, 74, 1752-1765.	0.4	129
63	Racial disparities in melanoma survival. Journal of the American Academy of Dermatology, 2016, 75, 983-991.	0.6	129
64	Inactivating germ-line and somatic mutations in polypeptide $\langle i \rangle N \langle i \rangle$ -acetylgalactosaminyltransferase 12 in human colon cancers. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 12921-12925.	3.3	128
65	Identifying DNA methylation biomarkers for non-endoscopic detection of Barrett's esophagus. Science Translational Medicine, 2018, 10, .	5.8	127
66	A nomogram for individualized estimation of survival among patients with brain metastasis. Neuro-Oncology, 2012, 14, 910-918.	0.6	126
67	Geneâ€specific criteria for <i>PTEN</i> variant curation: Recommendations from the ClinGen PTEN Expert Panel. Human Mutation, 2018, 39, 1581-1592.	1.1	123
68	An independently validated survival nomogram for lower-grade glioma. Neuro-Oncology, 2020, 22, 665-674.	0.6	123
69	Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma. Journal of Neurosurgery, 2008, 108, 642-648.	0.9	122
70	Females have the survival advantage in glioblastoma. Neuro-Oncology, 2018, 20, 576-577.	0.6	122
71	Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium. Neuro-Oncology, 2018, 20, 873-884.	0.6	119
72	FGFR2 and other loci identified in genome-wide association studies are associated with breast cancer in African-American and younger women. Carcinogenesis, 2010, 31, 1417-1423.	1.3	110

#	Article	IF	CITATIONS
73	An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. Neuro-Oncology, 2017, 19, now208.	0.6	109
74	Melanoma in adolescents and young adults (ages 15-39 years): United States, 1999-2006. Journal of the American Academy of Dermatology, 2011, 65, S38.e1-S38.e13.	0.6	107
7 5	Second Malignant Neoplasms in Patients With Cowden Syndrome With Underlying Germline <i>PTEN</i> Mutations. Journal of Clinical Oncology, 2014, 32, 1818-1824.	0.8	105
76	Incidence of vestibular schwannomas in the United States. Journal of Neuro-Oncology, 2015, 124, 223-228.	1.4	105
77	Incidence trends of invasive cervical cancer in the United States by combined race and ethnicity. Cancer Causes and Control, 2009, 20, 1129-1138.	0.8	101
78	The descriptive epidemiology of atypical teratoid/rhabdoid tumors in the United States, 2001-2010. Neuro-Oncology, 2014, 16, 1392-1399.	0.6	100
79	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nature Communications, 2013, 4, 1627.	5.8	98
80	Trends in central nervous system tumor incidence relative to other common cancers in adults, adolescents, and children in the United States, 2000 to 2010. Cancer, 2015, 121, 102-112.	2.0	98
81	Years of potential life lost for brain and CNS tumors relative to other cancers in adults in the United States, 2010. Neuro-Oncology, 2016, 18, 70-77.	0.6	90
82	15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 9409-9413.	3.3	89
83	Approaching a Scientific Consensus on the Association between Allergies and Glioma Risk: A Report from the Glioma International Case-Control Study. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 282-290.	1.1	89
84	Current State of Our Knowledge on Brain Tumor Epidemiology. Current Neurology and Neuroscience Reports, 2011, 11, 329-335.	2.0	86
85	Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era. JAMA Oncology, 2017, 3, 784.	3.4	83
86	Glioblastoma survival. Current Opinion in Neurology, 2014, 27, 666-674.	1.8	82
87	Sex Differences in Cancer Incidence and Survival: A Pan-Cancer Analysis. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1389-1397.	1.1	82
88	A population-based study of racial and ethnic differences in survival among women with invasive cervical cancer: Analysis of Surveillance, Epidemiology, and End Results data. Gynecologic Oncology, 2005, 97, 550-558.	0.6	81
89	Associations between Polymorphisms in DNA Repair Genes and Glioblastoma. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1118-1126.	1.1	81
90	Epidemiology of Intracranial Gliomas. Progress in Neurological Surgery, 2018, 30, 1-11.	1.3	78

#	Article	IF	Citations
91	The tumor suppressor CDKN3 controls mitosis. Journal of Cell Biology, 2013, 201, 997-1012.	2.3	77
92	Relative survival rates and patterns of diagnosis analyzed by time period for individuals with primary malignant brain tumor, 1973–1997. Journal of Neurosurgery, 2003, 99, 458-466.	0.9	76
93	Survivorship in adults with malignant brain and other central nervous system tumor from 2000–2014. Neuro-Oncology, 2018, 20, vii6-vii16.	0.6	76
94	Molecular Subtypes of Glioblastoma Are Relevant to Lower Grade Glioma. PLoS ONE, 2014, 9, e91216.	1.1	76
95	<i>LIN28B</i> Polymorphisms Influence Susceptibility to Epithelial Ovarian Cancer. Cancer Research, 2011, 71, 3896-3903.	0.4	75
96	Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers. Nature Communications, 2020, 11, 3353.	5.8	75
97	Racial differences in survival after diagnosis with primary malignant brain tumor. Cancer, 2003, 98, 603-609.	2.0	74
98	GLIOGENEâ€"an International Consortium to Understand Familial Glioma. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1730-1734.	1.1	74
99	Association of germline microRNA SNPs in pre-miRNA flanking region and breast cancer risk and survival: the Carolina Breast Cancer Study. Cancer Causes and Control, 2013, 24, 1099-1109.	0.8	72
100	Examining Population Stratification via Individual Ancestry Estimates versus Self-Reported Race. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1545-1551.	1.1	71
101	Racial/ethnic differences in survival among elderly patients with a primary glioblastoma. Journal of Neuro-Oncology, 2007, 85, 171-80.	1.4	71
102	The microRNAs, MiRâ€31 and MiRâ€375, as candidate markers in Barrett's esophageal carcinogenesis. Genes Chromosomes and Cancer, 2012, 51, 473-479.	1.5	71
103	Network Signatures of Survival in Glioblastoma Multiforme. PLoS Computational Biology, 2013, 9, e1003237.	1.5	71
104	Melanoma Incidence in Children and Adolescents: Decreasing Trends inÂthe United States. Journal of Pediatrics, 2015, 166, 1505-1513.	0.9	71
105	Glioma incidence and survival variations by countyâ€level socioeconomic measures. Cancer, 2019, 125, 3390-3400.	2.0	68
106	Information on ancestry from genetic markers. Genetic Epidemiology, 2004, 26, 305-315.	0.6	64
107	Inherited Variants in Mitochondrial Biogenesis Genes May Influence Epithelial Ovarian Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1131-1145.	1.1	62
108	Induction of KIAA1199/CEMIP is associated with colon cancer phenotype and poor patient survival. Oncotarget, 2015, 6, 30500-30515.	0.8	62

#	Article	IF	Citations
109	Understanding inherited genetic risk of adult glioma – a review. Neuro-Oncology Practice, 2016, 3, 10-16.	1.0	62
110	Incidence and survival trends for medulloblastomas in the United States from 2001 to 2013. Journal of Neuro-Oncology, 2017, 135, 433-441.	1.4	62
111	Treatment and surgical factors associated with longer-term glioblastoma survival: a National Cancer Database study. Neuro-Oncology Advances, 2020, 2, 1-10.	0.4	62
112	Ethnic differences in survival among women with ovarian carcinoma. Cancer, 2002, 94, 1886-1893.	2.0	61
113	A multi-center population-based case–control study of ovarian cancer in African-American women: the African American Cancer Epidemiology Study (AACES). BMC Cancer, 2014, 14, 688.	1.1	61
114	Ancestry Estimation and Correction for Population Stratification in Molecular Epidemiologic Association Studies. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 471-477.	1.1	60
115	Issues of Diagnostic Review in Brain Tumor Studies: From the Brain Tumor Epidemiology Consortium. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 484-489.	1.1	60
116	Sex differences in oncogenic mutational processes. Nature Communications, 2020, 11, 4330.	5.8	60
117	Stereotactic laser ablation as treatment for brain metastases that recur after stereotactic radiosurgery: a multiinstitutional experience. Neurosurgical Focus, 2016, 41, E11.	1.0	59
118	Nonmalignant and malignant meningioma incidence and survival in the elderly, 2005–2015, using the Central Brain Tumor Registry of the United States. Neuro-Oncology, 2019, 21, 380-391.	0.6	59
119	Characterizing Mutational Heterogeneity in a Glioblastoma Patient with Double Recurrence. PLoS ONE, 2012, 7, e35262.	1.1	58
120	Descriptive Epidemiology of Spinal Meningiomas in the United States. Spine, 2015, 40, E886-E889.	1.0	56
121	Sex-specific glioma genome-wide association study identifies new risk locus at 3p21.31 in females, and finds sex-differences in risk at 8q24.21. Scientific Reports, 2018, 8, 7352.	1.6	56
122	Meningiomas: causes and risk factors. Neurosurgical Focus, 2007, 23, E2.	1.0	54
123	Common genetic variation in adiponectin, leptin, and leptin receptor and association with breast cancer subtypes. Breast Cancer Research and Treatment, 2011, 129, 593-606.	1.1	54
124	Expression of the \hat{l} ±-tocopherol transfer protein gene is regulated by oxidative stress and common single-nucleotide polymorphisms. Free Radical Biology and Medicine, 2012, 53, 2318-2326.	1.3	52
125	Management of malignant colonic polyps: A populationâ€based analysis of colonoscopic polypectomy versus surgery. Cancer, 2012, 118, 651-659.	2.0	52
126	Sex-specific gene and pathway modeling of inherited glioma risk. Neuro-Oncology, 2019, 21, 71-82.	0.6	52

#	Article	IF	CITATIONS
127	Descriptive epidemiology of germ cell tumors of the central nervous system diagnosed in the United States from 2006 to 2015. Journal of Neuro-Oncology, 2019, 143, 251-260.	1.4	52
128	Review and Evaluation of Methods Correcting for Population Stratification with a Focus on Underlying Statistical Principles. Human Heredity, 2008, 66, 67-86.	0.4	50
129	5-Fluorouracil Enhances the Antitumor Activity of the Glutaminase Inhibitor CB-839 against <i>PIK3CA</i> -Mutant Colorectal Cancers. Cancer Research, 2020, 80, 4815-4827.	0.4	49
130	Complete prevalence of malignant primary brain tumors registry data in the United States compared with other common cancers, 2010. Neuro-Oncology, 2017, 19, now252.	0.6	48
131	Dissecting the Within-Africa Ancestry of Populations of African Descent in the Americas. PLoS ONE, 2011, 6, e14495.	1.1	48
132	Gene interaction enrichment and network analysis to identify dysregulated pathways and their interactions in complex diseases. BMC Systems Biology, 2012, 6, 65.	3.0	47
133	Familial Aggregation of Glioma: A Pooled Analysis. American Journal of Epidemiology, 2010, 172, 1099-1107.	1.6	46
134	The CBTRUS story: providing accurate population-based statistics on brain and other central nervous system tumors for everyone. Neuro-Oncology, 2018, 20, 295-298.	0.6	46
135	Genome-Wide Methylation Analyses in Glioblastoma Multiforme. PLoS ONE, 2014, 9, e89376.	1.1	45
136	Whole genome sequence analysis links chromothripsis to EGFR, MDM2, MDM4, and CDK4 amplification in glioblastoma. Oncoscience, 2015, 2, 618-628.	0.9	45
137	The Glioma International Case-Control Study: A Report From the Genetic Epidemiology of Glioma International Consortium. American Journal of Epidemiology, 2016, 183, kwv235.	1.6	45
138	miR-4516 predicts poor prognosis and functions as a novel oncogene via targeting PTPN14 in human glioblastoma. Oncogene, 2019, 38, 2923-2936.	2.6	45
139	Loss of H3K27me3 in meningiomas. Neuro-Oncology, 2021, 23, 1282-1291.	0.6	45
140	Survival of women diagnosed with malignant, mixed mullerian tumors of the ovary (OMMMT). Gynecologic Oncology, 2004, 93, 506-512.	0.6	44
141	Assessment of Familiality, Obesity and Other Risk Factors for Early Age of Cancer Diagnosis in Adenocarcinomas of the Esophagus and Gastroesophageal Junction. American Journal of Gastroenterology, 2009, 104, 1913-1921.	0.2	44
142	Genome-Wide High-Density SNP Linkage Search for Glioma Susceptibility Loci: Results from the Gliogene Consortium. Cancer Research, 2011, 71, 7568-7575.	0.4	44
143	Laser interstitial thermal therapy followed by minimal-access transsulcal resection for the treatment of large and difficult to access brain tumors. Neurosurgical Focus, 2016, 41, E14.	1.0	44
144	Estimating the annual frequency of synchronous brain metastasis in the United States 2010–2013: a population-based study. Journal of Neuro-Oncology, 2017, 134, 55-64.	1.4	44

#	Article	IF	CITATIONS
145	Inhibition of PI3K/Akt/mTOR signaling in PI3KR2-overexpressing colon cancer stem cells reduces tumor growth due to apoptosis. Oncotarget, 2017, 8, 50476-50488.	0.8	43
146	Epidemiology of Brain and Other CNS Tumors. Current Neurology and Neuroscience Reports, 2021, 21, 68.	2.0	43
147	The Misclassification of Diffuse Gliomas: Rates and Outcomes. Clinical Cancer Research, 2019, 25, 2656-2663.	3. 2	42
148	Medical treatment of recurrent meningiomas. Expert Review of Neurotherapeutics, 2011, 11, 1425-1432.	1.4	41
149	Incidence patterns for primary malignant spinal cord gliomas: a Surveillance, Epidemiology, and End Results study. Journal of Neurosurgery: Spine, 2011, 14, 742-747.	0.9	41
150	Aberrant Vimentin Methylation Is Characteristic of Upper Gastrointestinal Pathologies. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 594-600.	1.1	41
151	Single cell RNA sequencing of AML initiating cells reveals RNA-based evolution during disease progression. Leukemia, 2021, 35, 2799-2812.	3.3	41
152	Comparative Brain and Central Nervous System Tumor Incidence and Survival between the United States and Taiwan Based on Population-Based Registry. Frontiers in Public Health, 2016, 4, 151.	1.3	40
153	Association between Body Powder Use and Ovarian Cancer: The African American Cancer Epidemiology Study (AACES). Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1411-1417.	1.1	40
154	Dietary inflammatory index and risk of epithelial ovarian cancer in African American women. International Journal of Cancer, 2017, 140, 535-543.	2.3	40
155	An independently validated nomogram for isocitrate dehydrogenase-wild-type glioblastoma patient survival. Neuro-Oncology Advances, 2019, 1, vdz007.	0.4	40
156	Primary brain and other central nervous system tumors in the United States (2014-2018): A summary of the CBTRUS statistical report for clinicians. Neuro-Oncology Practice, 2022, 9, 165-182.	1.0	40
157	A Segregation Analysis of Barrett's Esophagus and Associated Adenocarcinomas. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 666-674.	1.1	39
158	Glioblastoma incidence rate trends in Canada and the United States compared with England, 1995–2015. Neuro-Oncology, 2020, 22, 301-302.	0.6	39
159	Impact of atopy on risk of glioma: a Mendelian randomisation study. BMC Medicine, 2018, 16, 42.	2.3	38
160	Risk and Survival of Cutaneous Melanoma Diagnosed Subsequent to a Previous Cancer. Archives of Dermatology, 2011, 147, 1395.	1.7	37
161	Use of colonoscopy for polyp surveillance in Medicare beneficiaries. Cancer, 2013, 119, 1800-1807.	2.0	37
162	Years of life lived with disease and years of potential life lost in children who die of cancer in the United States, 2009. Cancer Medicine, 2015, 4, 608-619.	1.3	36

#	Article	IF	CITATIONS
163	History of chickenpox in glioma risk: a report from the glioma international case–control study (<scp>GICC</scp>). Cancer Medicine, 2016, 5, 1352-1358.	1.3	36
164	Sex is an important prognostic factor for glioblastoma but not for nonglioblastoma. Neuro-Oncology Practice, 2019, 6, 451-462.	1.0	36
165	Descriptive epidemiology of craniopharyngiomas in the United States. Pituitary, 2021, 24, 517-522.	1.6	36
166	Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004–2012, varying). Journal of Neuro-Oncology, 2016, 130, 31-42.	1.4	35
167	Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES). International Journal of Gynecological Pathology, 2019, 38, 157-170.	0.9	34
168	Pediatric brain tumors in Non-Hispanics, Hispanics, African Americans and Asians: differences in survival after diagnosis. Cancer Causes and Control, 2005, 16, 587-592.	0.8	33
169	Computational identification of multi-omic correlates of anticancer therapeutic response. BMC Genomics, 2014, 15, S2.	1.2	33
170	Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. International Journal of Epidemiology, 2018, 47, 460-472.	0.9	33
171	Glioma-related seizures in relation to histopathological subtypes: a report from the glioma international case–control study. Journal of Neurology, 2018, 265, 1432-1442.	1.8	32
172	Influence of obesity-related risk factors in the aetiology of glioma. British Journal of Cancer, 2018, 118, 1020-1027.	2.9	32
173	Magnetic Resonance Fingerprinting to Characterize Childhood and Young Adult Brain Tumors. Pediatric Neurosurgery, 2019, 54, 310-318.	0.4	32
174	Dietary carbohydrate intake, glycaemic load, glycaemic index and ovarian cancer risk in African-American women. British Journal of Nutrition, 2016, 115, 694-702.	1.2	31
175	Anemia and Red Blood Cell Indices Predict HIV-Associated Neurocognitive Impairment in the Highly Active Antiretroviral Therapy Era. Journal of Infectious Diseases, 2016, 213, 1065-1073.	1.9	31
176	Models of epigenetic age capture patterns of DNA methylation in glioma associated with molecular subtype, survival, and recurrence. Neuro-Oncology, 2018, 20, 942-953.	0.6	31
177	Al-based prognostic imaging biomarkers for precision neuro-oncology: the ReSPOND consortium. Neuro-Oncology, 2020, 22, 886-888.	0.6	31
178	Radiomic analysis of magnetic resonance fingerprinting in adult brain tumors. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 683-693.	3.3	31
179	Reproductive and Hormonal Risk Factors for Ductal Carcinoma In situ of the Breast. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1507-1514.	1.1	30
180	Inverse association of PPAR $\hat{\mathbf{I}}^3$ agonists use and high grade glioma development. Journal of Neuro-Oncology, 2010, 100, 233-239.	1.4	30

#	Article	IF	Citations
181	Description of selected characteristics of familial glioma patients – Results from the Gliogene Consortium. European Journal of Cancer, 2013, 49, 1335-1345.	1.3	30
182	Dairy, calcium, vitamin D and ovarian cancer risk in African–American women. British Journal of Cancer, 2016, 115, 1122-1130.	2.9	30
183	Cerebrospinal fluid cell-free mitochondrial DNA is associated with HIV replication, iron transport, and mild HIV-associated neurocognitive impairment. Journal of Neuroinflammation, 2017, 14, 72.	3.1	30
184	A novel prognostic sixâ€CpG signature in glioblastomas. CNS Neuroscience and Therapeutics, 2018, 24, 167-177.	1.9	30
185	Malignant primary brain and other central nervous system tumors diagnosed in Canada from 2009 to 2013. Neuro-Oncology, 2019, 21, 360-369.	0.6	30
186	Response to "The epidemiology of glioma in adults: a 'state of the science' review". Neuro-Oncology, 2015, 17, 624-626.	0.6	29
187	Importance of the intersection of age and sex to understand variation in incidence and survival for primary malignant gliomas. Neuro-Oncology, 2022, 24, 302-310.	0.6	29
188	Epidemiology of brainstem high-grade gliomas in children and adolescents in the United States, 2000-2017. Neuro-Oncology, 2021, 23, 990-998.	0.6	28
189	Dietary fatty acids, luminal modifiers, and risk of colorectal cancer. International Journal of Cancer, 2010, 127, 942-951.	2.3	27
190	Genetic and environmental influences on plasma vitamin D binding protein concentrations. Translational Research, 2015, 165, 667-676.	2.2	27
191	The epidemiology of central and extraventricular neurocytoma in the United States between 2006 and 2014. Journal of Neuro-Oncology, 2019, 143, 123-127.	1.4	27
192	Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples. Nature Communications, 2020, 11, 4748.	5.8	27
193	Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States. Neuro-Oncology, 2022, 24, 1989-2000.	0.6	27
194	Survey of familial glioma and role of germline p16 INK4A /p14 ARF and p53 mutation. Familial Cancer, 2010, 9, 413-421.	0.9	26
195	Joint Effects of Alcohol Consumption and Polymorphisms in Alcohol and Oxidative Stress Metabolism Genes on Risk of Head and Neck Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2438-2449.	1.1	26
196	Variation in Age at Cancer Diagnosis in Familial versus Nonfamilial Barrett's Esophagus. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 376-383.	1.1	26
197	Protein Markers Predict Survival in Glioma Patients. Molecular and Cellular Proteomics, 2016, 15, 2356-2365.	2.5	26
198	RNA Sequencing Identifies Transcriptionally Viable Gene Fusions in Esophageal Adenocarcinomas. Cancer Research, 2016, 76, 5628-5633.	0.4	26

#	Article	IF	CITATIONS
199	Genomeâ€wide association study of HIVâ€associated neurocognitive disorder (HAND): A CHARTER group study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2017, 174, 413-426.	1.1	26
200	Cerebrospinal Fluid Ceruloplasmin, Haptoglobin, and Vascular Endothelial Growth Factor Are Associated with Neurocognitive Impairment in Adults with HIV Infection. Molecular Neurobiology, 2019, 56, 3808-3818.	1.9	26
201	Cancer Imaging Phenomics via CaPTk: Multi-Institutional Prediction of Progression-Free Survival and Pattern of Recurrence in Glioblastoma. JCO Clinical Cancer Informatics, 2020, 4, 234-244.	1.0	26
202	JAM-A functions as a female microglial tumor suppressor in glioblastoma. Neuro-Oncology, 2020, 22, 1591-1601.	0.6	26
203	Transcriptome-Wide Association Study Identifies New Candidate Susceptibility Genes for Glioma. Cancer Research, 2019, 79, 2065-2071.	0.4	26
204	Family History of Cancer in Benign Brain Tumor Subtypes Versus Gliomas. Frontiers in Oncology, 2012, 2, 19.	1.3	25
205	Methylation markers of malignant potential in meningiomas. Journal of Neurosurgery, 2013, 119, 899-906.	0.9	25
206	Obesity, weight gain, and ovarian cancer risk in African American women. International Journal of Cancer, 2016, 139, 593-600.	2.3	25
207	Epidemiology of Anorectal Melanoma in the United States. Dermatologic Surgery, 2016, 42, 94-99.	0.4	25
208	Multiscale, multimodal analysis of tumor heterogeneity in IDH1 mutant vs wild-type diffuse gliomas. PLoS ONE, 2019, 14, e0219724.	1.1	25
209	Descriptive epidemiology of chordomas in the United States. Journal of Neuro-Oncology, 2020, 148, 173-178.	1.4	25
210	Functional polymorphisms to modulate luminal lipid exposure and risk of colorectal cancer. Cancer Epidemiology, 2010, 34, 291-297.	0.8	24
211	Completeness and concordancy of WHO grade assignment for brain and central nervous system tumors in the United States, 2004–2011. Journal of Neuro-Oncology, 2015, 123, 43-51.	1.4	24
212	Integrated genomic analysis of survival outliers in glioblastoma. Neuro-Oncology, 2017, 19, now269.	0.6	23
213	Analgesic medication use and risk of epithelial ovarian cancer in African American women. British Journal of Cancer, 2016, 114, 819-825.	2.9	23
214	Mendelian randomisation study of the relationship between vitamin D and risk of glioma. Scientific Reports, 2018, 8, 2339.	1.6	23
215	Perceived discrimination, trust in physicians, and prolonged symptom duration before ovarian cancer diagnosis in the African American Cancer Epidemiology Study. Cancer, 2019, 125, 4442-4451.	2.0	23
216	Lifetime Occurrence of Brain Metastases Arising from Lung, Breast, and Skin Cancers in the Elderly: A SEER-Medicare Study. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 917-925.	1.1	23

#	Article	IF	Citations
217	Glioma risk associated with extent of estimated European genetic ancestry in African Americans and Hispanics. International Journal of Cancer, 2020, 146, 739-748.	2.3	23
218	Diverticulosis and the Risk of Interval Colorectal Cancer. Digestive Diseases and Sciences, 2014, 59, 2765-2772.	1.1	22
219	Targeted Sequencing in Chromosome 17q Linkage Region Identifies Familial Glioma Candidates in the Gliogene Consortium. Scientific Reports, 2015, 5, 8278.	1.6	22
220	Is all inflammation within temporal artery biopsies temporal arteritis?. Human Pathology, 2016, 57, 17-21.	1.1	22
221	Assessing the impact of global versus local ancestry in association studies. BMC Proceedings, 2009, 3, S107.	1.8	21
222	Decision Tree–Based Modeling of Androgen Pathway Genes and Prostate Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1146-1155.	1.1	21
223	Risk of subsequent cancer following a primary CNS tumor. Journal of Neuro-Oncology, 2013, 112, 285-295.	1.4	21
224	Reproductive factors and ovarian cancer risk in African-American women. Annals of Epidemiology, 2016, 26, 654-662.	0.9	21
225	Multi-institutional external validation of a novel glioblastoma prognostic nomogram incorporating MGMT methylation. Journal of Neuro-Oncology, 2017, 134, 331-338.	1.4	21
226	Ageâ€specific genomeâ€wide association study in glioblastoma identifies increased proportion of  lower grade glioma'â€like features associated with younger age. International Journal of Cancer, 2018, 143, 2359-2366.	2.3	21
227	Primary central nervous system lymphoma in patients with and without HIV infection: a multicenter study and comparison with U.S national data. Cancer Causes and Control, 2019, 30, 477-488.	0.8	21
228	Genome-wide Analysis of Common Copy Number Variation and Epithelial Ovarian Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1117-1126.	1.1	21
229	Electronic Medical Record Search Engine (EMERSE): An Information Retrieval Tool for Supporting Cancer Research. JCO Clinical Cancer Informatics, 2020, 4, 454-463.	1.0	21
230	The epidemiology of spinal schwannoma in the United States between 2006 and 2014. Journal of Neurosurgery: Spine, 2020, 32, 661-666.	0.9	21
231	Racial and ethnic disparities in the incidence of invasive cervical cancer in Florida. Cancer, 2009, 115, 3991-4000.	2.0	20
232	A Variable Age of Onset Segregation Model for Linkage Analysis, with Correction for Ascertainment, Applied to Glioma. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 2242-2251.	1.1	20
233	Insight in glioma susceptibility through an analysis of 6p22.3, 12p13.33-12.1, 17q22-23.2 and 18q23 SNP genotypes in familial and non-familial glioma. Human Genetics, 2012, 131, 1507-1517.	1.8	20
234	Trial Prospector: Matching Patients with Cancer Research Studies Using an Automated and Scalable Approach. Cancer Informatics, 2014, 13, CIN.S19454.	0.9	20

#	Article	IF	CITATIONS
235	Tailoring Education to Perceived Fall Risk in Hospitalized Patients With Cancer: A Randomized, Controlled Trial. Clinical Journal of Oncology Nursing, 2016, 20, 84-89.	0.3	20
236	A comparison of relative survival and causeâ€specific survival methods to measure net survival in cancer populations. Cancer Medicine, 2018, 7, 4773-4780.	1.3	20
237	A population study of clinical trial accrual for women and minorities in neuro-oncology following the NIH Revitalization Act. Neuro-Oncology, 2022, 24, 1341-1349.	0.6	20
238	Tocopherol Transfer Protein Sensitizes Prostate Cancer Cells to Vitamin E. Journal of Biological Chemistry, 2010, 285, 35578-35589.	1.6	19
239	MicroRNA Processing and Binding Site Polymorphisms Are Not Replicated in the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1793-1797.	1.1	19
240	Lack of association between modifiable exposures and glioma risk: A Mendelian randomisation analysis. Neuro-Oncology, 2020, 22, 207-215.	0.6	19
241	Partnership for defining the impact of 12 selected rare CNS tumors: a report from the CBTRUS and the NCI-CONNECT. Journal of Neuro-Oncology, 2019, 144, 53-63.	1.4	19
242	MRI image analysis methods and applications: an algorithmic perspective using brain tumors as an exemplar. Neuro-Oncology Advances, 2020, 2, vdaa049.	0.4	19
243	Reimagining pilocytic astrocytomas in the context of pediatric low-grade gliomas. Neuro-Oncology, 2021, 23, 1634-1646.	0.6	19
244	Informativeness of the CODIS STR Loci for Admixture Analysis. Journal of Forensic Sciences, 2005, 50, 1-5.	0.9	19
245	Integrative analysis of novel hypomethylation and gene expression signatures in glioblastomas. Oncotarget, 2017, 8, 89607-89619.	0.8	19
246	Gene markers in brain tumors: What the epileptologist should know. Epilepsia, 2013, 54, 25-29.	2.6	18
247	Prognostic significance of preoperative neutrophilia on recurrence-free survival in meningioma. Neuro-Oncology, 2017, 19, 1503-1510.	0.6	18
248	Identification of novel epithelial ovarian cancer loci in women of African ancestry. International Journal of Cancer, 2020, 146, 2987-2998.	2.3	18
249	Relative survival after diagnosis with a primary brain or other central nervous system tumor in the National Program of Cancer Registries, 2004 to 2014. Neuro-Oncology Practice, 2020, 7, 306-312.	1.0	18
250	The ratio of HLA-DR and VNN2+ expression on CD14+ myeloid derived suppressor cells can distinguish glioblastoma from radiation necrosis patients. Journal of Neuro-Oncology, 2017, 134, 189-196.	1.4	18
251	Genetic variation in estrogen and progesterone pathway genes and breast cancer risk: an exploration of tumor subtype-specific effects. Cancer Causes and Control, 2015, 26, 121-131.	0.8	17
252	Incidence and survival trends in oligodendrogliomas and anaplastic oligodendrogliomas in the United States from 2000 to 2013: a CBTRUS Report. Journal of Neuro-Oncology, 2017, 133, 17-25.	1.4	17

#	Article	IF	CITATIONS
253	Cancer collection efforts in the United States provide clinically relevant data on all primary brain and other CNS tumors. Neuro-Oncology Practice, 2019, 6, 330-339.	1.0	17
254	Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Crossâ€sectional and longitudinal analysis using two large national registries. Cancer Medicine, 2021, 10, 3862-3872.	1.3	17
255	Pharmacogenomic Approach to Identify Drug Sensitivity in Small-Cell Lung Cancer. PLoS ONE, 2014, 9, e106784.	1.1	16
256	A Trial Online Educational Melanoma Program Aimed at the Hispanic Population Improves Knowledge and Behaviors. Dermatologic Surgery, 2016, 42, 672-676.	0.4	16
257	Supplemental Selenium May Decrease Ovarian Cancer Risk in African-American Women. Journal of Nutrition, 2017, 147, 621-627.	1.3	16
258	Lifetime number of ovulatory cycles and epithelial ovarian cancer risk in African American women. Cancer Causes and Control, 2017, 28, 405-414.	0.8	16
259	Peripheral Blood Mitochondrial DNA Copy Number Obtained From Genome-Wide Genotype Data Is Associated With Neurocognitive Impairment in Persons With Chronic HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, e95-e102.	0.9	16
260	Primary brain and other central nervous system tumors in Appalachia: regional differences in incidence, mortality, and survival. Journal of Neuro-Oncology, 2019, 142, 27-38.	1.4	16
261	European genetic ancestry associated with risk of childhood ependymoma. Neuro-Oncology, 2020, 22, 1637-1646.	0.6	16
262	Identification of Variants in Primary and Recurrent Glioblastoma Using a Cancer-Specific Gene Panel and Whole Exome Sequencing. PLoS ONE, 2015, 10, e0124178.	1.1	16
263	Replication of GWAS "Hits―by Race for Breast and Prostate Cancers in European Americans and African Americans. Frontiers in Genetics, 2011, 2, 37.	1.1	15
264	Plasma Proteome Analysis Reveals Overlapping, yet Distinct Mechanisms of Immune Activation in Chronic HCV and HIV Infections. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 563-571.	0.9	15
265	Racial disparities and insurance status: An epidemiological analysis of Ohio melanoma patients. Journal of the American Academy of Dermatology, 2018, 78, 998-1000.	0.6	15
266	Aspirin, NSAIDs, and Glioma Risk: Original Data from the Glioma International Case–Control Study and a Meta-analysis. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 555-562.	1.1	15
267	Gliomas display distinct sex-based differential methylation patterns based on molecular subtype. Neuro-Oncology Advances, 2020, 2, vdaa002.	0.4	15
268	Association of cancer center type with treatment patterns and overall survival for patients with sacral and spinal chordomas: an analysis of the National Cancer Database from 2004 to 2015. Journal of Neurosurgery: Spine, 2020, 32, 311-320.	0.9	15
269	The Epidemiology of Central Nervous System Tumors. Hematology/Oncology Clinics of North America, 2022, 36, 23-42.	0.9	15
270	Effects of polymorphisms in alcohol metabolism and oxidative stress genes on survival from head and neck cancer. Cancer Epidemiology, 2013, 37, 479-491.	0.8	14

#	Article	IF	CITATIONS
271	Single-Nucleotide Polymorphisms in Nucleotide Excision Repair Genes, Cigarette Smoking, and the Risk of Head and Neck Cancer. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1428-1445.	1.1	14
272	Conditional survival after diagnosis with malignant brain and central nervous system tumor in the United States, 1995–2012. Journal of Neuro-Oncology, 2016, 128, 419-429.	1.4	14
273	Is mortality due to primary malignant brain and other central nervous system tumors decreasing?. Journal of Neuro-Oncology, 2017, 133, 265-275.	1.4	14
274	Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas. Clinical Epigenetics, 2019, 11, 76.	1.8	14
275	An updated histology recode for the analysis of primary malignant and nonmalignant brain and other central nervous system tumors in the Surveillance, Epidemiology, and End Results Program. Neuro-Oncology Advances, 2021, 3, vdaa175.	0.4	14
276	Sex differences in esophageal cancer overall and by histological subtype. Scientific Reports, 2022, 12, 5248.	1.6	14
277	Risk of subsequent primary malignancies after dermatofibrosarcoma protuberans diagnosis: A national study. Journal of the American Academy of Dermatology, 2013, 68, 790-796.	0.6	13
278	Validation of an automated tractography method for the optic radiations as a biomarker of visual acuity in neurofibromatosis-associated optic pathway glioma. Experimental Neurology, 2018, 299, 308-316.	2.0	13
279	Bevacizumab for the treatment of non-small cell lung cancer patients with synchronous brain metastases. Scientific Reports, 2019, 9, 17792.	1.6	13
280	Sulindac reversal of 15-PGDH-mediated resistance to colon tumor chemoprevention with NSAIDs. Carcinogenesis, 2015, 36, 291-298.	1.3	12
281	Recreational physical activity and ovarian cancer risk in African American women. Cancer Medicine, 2016, 5, 1319-1327.	1.3	12
282	Socioeconomic Status in Relation to the Risk of Ovarian Cancer in African-American Women: A Population-Based Case-Control Study. American Journal of Epidemiology, 2016, 184, 274-283.	1.6	12
283	Dietary Quality and Ovarian Cancer Risk in African-American Women. American Journal of Epidemiology, 2017, 185, 1281-1289.	1.6	12
284	Recreational physical activity and survival in African-American women with ovarian cancer. Cancer Causes and Control, 2018, 29, 77-86.	0.8	12
285	Prognostic models for patients with brain metastases after stereotactic radiosurgery with or without whole brain radiotherapy: a validation study. Journal of Neuro-Oncology, 2018, 140, 341-349.	1.4	12
286	A fiveâ€CpG signature of microRNA methylation in nonâ€Gâ€CIMP glioblastoma. CNS Neuroscience and Therapeutics, 2019, 25, 937-950.	1.9	12
287	Effect of Cultural, Folk, and Religious Beliefs and Practices on Delays in Diagnosis of Ovarian Cancer in African American Women. Journal of Women's Health, 2019, 28, 444-451.	1.5	12
288	Individual, Social, and Societal Correlates of Health-Related Quality of Life Among African American Survivors of Ovarian Cancer: Results from the African American Cancer Epidemiology Study. Journal of Women's Health, 2019, 28, 284-293.	1.5	12

#	Article	IF	CITATIONS
289	Partitioned glioma heritability shows subtype-specific enrichment in immune cells. Neuro-Oncology, 2021, 23, 1304-1314.	0.6	12
290	Multi-institutional noninvasive in vivo characterization of <i>IDH</i> , 1p/19q, and EGFRvIII in glioma using neuro-Cancer Imaging Phenomics Toolkit (neuro-CaPTk). Neuro-Oncology Advances, 2020, 2, iv22-iv34.	0.4	12
291	Germline Copy Number Variation and Ovarian Cancer Survival. Frontiers in Genetics, 2012, 3, 142.	1.1	11
292	Germline rearrangements in families with strong family history of glioma and malignant melanoma, colon, and breast cancer. Neuro-Oncology, 2014, 16, 1333-1340.	0.6	11
293	Methylated <i>B3GAT2</i> and <i>ZNF793</i> Are Potential Detection Biomarkers for Barrett's Esophagus. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1890-1897.	1.1	11
294	International Differences in Treatment and Clinical Outcomes for High Grade Glioma. PLoS ONE, 2015, 10, e0129602.	1.1	11
295	Proteome and Protein Network Analyses of Memory T Cells Find Altered Translation and Cell Stress Signaling in Treated Human Immunodeficiency Virus Patients Exhibiting Poor CD4 Recovery. Open Forum Infectious Diseases, 2016, 3, ofw037.	0.4	11
296	Premenopausal Hysterectomy and Risk of Ovarian Cancer in African-American Women. American Journal of Epidemiology, 2017, 186, 46-53.	1.6	11
297	Pilocytic astrocytoma: Where do they belong in cancer reporting?. Neuro-Oncology, 2019, 22, 298-300.	0.6	11
298	Sex Differences in Time to Treat and Outcomes for Gliomas. Frontiers in Oncology, 2021, 11, 630597.	1.3	11
299	A nonrandomized trial of vitamin D supplementation for Barrett's esophagus. PLoS ONE, 2017, 12, e0184928.	1.1	11
300	Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. Journal of Neuro-Oncology, 2021, 155, 363-372.	1.4	11
301	Colonic 15-PGDH Levels Are Stable Across Distance and Time and Are Not Perturbed by Aspirin Intervention. Digestive Diseases and Sciences, 2013, 58, 2615-2622.	1.1	10
302	The Association Between Body Mass Index and Presenting Symptoms in African American Women with Ovarian Cancer. Journal of Women's Health, 2016, 25, 571-578.	1.5	10
303	Predicting Barrett's Esophagus in Families: An Esophagus Translational Research Network (BETRNet) Model Fitting Clinical Data to a Familial Paradigm. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 727-735.	1.1	10
304	Benign gynecologic conditions are associated with ovarian cancer risk in African-American women: a case–control study. Cancer Causes and Control, 2018, 29, 1081-1091.	0.8	10
305	Gene Expression Changes Accompanying the Duodenal Adenoma-Carcinoma Sequence in Familial Adenomatous Polyposis. Clinical and Translational Gastroenterology, 2019, 10, e00053.	1.3	10
306	Racial/ethnic disparities in treatment pattern and time to treatment for adults with glioblastoma in the US. Journal of Neuro-Oncology, 2021, 152, 603-615.	1.4	10

#	Article	IF	Citations
307	Drug Intervention Response Predictions with PARADIGM (DIRPP) identifies drug resistant cancer cell lines and pathway mechanisms of resistance. Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing, 2014, , 125-35.	0.7	10
308	Psychosocial factors associated with genetic testing status among African American women with ovarian cancer: Results from the African American Cancer Epidemiology Study. Cancer, 2022, 128, 1252-1259.	2.0	10
309	Single nucleotide polymorphisms in nucleotide excision repair genes, cancer treatment, and head and neck cancer survival. Cancer Causes and Control, 2014, 25, 437-450.	0.8	9
310	Survival in Patients with High-Grade Spinal Meningioma: An Analysis of the National Cancer Database. World Neurosurgery, 2019, 129, e749-e753.	0.7	9
311	A Liquid Biopsy to Assess Brain Tumor Recurrence: Presence of Circulating Mo-MDSC and CD14+ VNN2+ Myeloid Cells as Biomarkers That Distinguish Brain Metastasis From Radiation Necrosis Following Stereotactic Radiosurgery. Neurosurgery, 2020, 88, E67-E72.	0.6	9
312	Searching for causal relationships of glioma: a phenome-wide Mendelian randomisation study. British Journal of Cancer, 2021, 124, 447-454.	2.9	9
313	Phase I clinical trial of the glutaminase inhibitor CB-839 plus capecitabine in patients with advanced solid tumors Journal of Clinical Oncology, 2018, 36, 2562-2562.	0.8	9
314	Detection of tumor-specific DNA methylation markers in the blood of patients with pituitary neuroendocrine tumors. Neuro-Oncology, 2022, 24, 1126-1139.	0.6	9
315	Sex Differences in Lung Cancer Treatment and Outcomes at a Large Hybrid Academic-Community Practice. JTO Clinical and Research Reports, 2022, 3, 100307.	0.6	9
316	Survival analysis of distant prostate cancer by decade (1973-1997) in the Detroit Metropolitan Surveillance, Epidemiology and End Results (SEER) Program registry: has outcome improved? (United) Tj ETQq0	0 Oor. g BT /0	Overlock 10 T
317	APOE and FABP2 Polymorphisms and History of Myocardial Infarction, Stroke, Diabetes, and Gallbladder Disease. Cholesterol, 2011, 2011, 1-9.	1.6	8
318	The Age-Specific Effect Modification of Male Sex for Ulcerated Cutaneous Melanoma. JAMA Dermatology, 2014, 150, 522.	2.0	8
319	Do race and age vary in non-malignant central nervous system tumor incidences in the United States?. Journal of Neuro-Oncology, 2017, 134, 269-277.	1.4	8
320	Correlation of higher levels of soluble TNF-R1 with a shorter survival, independent of age, in recurrent glioblastoma. Journal of Neuro-Oncology, 2017, 131, 449-458.	1.4	8
321	Prediagnostic Proinflammatory Dietary Potential Is Associated with All-Cause Mortality among African-American Women with High-Grade Serous Ovarian Carcinoma. Journal of Nutrition, 2019, 149, 1606-1616.	1.3	8
322	A Novel miR-146a-POU3F2/SMARCA5 Pathway Regulates Stemness and Therapeutic Response in Glioblastoma. Molecular Cancer Research, 2021, 19, 48-60.	1.5	8
323	Tumor Treating Fields for Glioblastoma Therapy During the COVID-19 Pandemic. Frontiers in Oncology, 2021, 11, 679702.	1.3	8
324	Epidemiology of vestibular schwannoma in the United States, 2004–2016. Neuro-Oncology Advances, 2020, 2, vdaa135.	0.4	8

#	Article	IF	CITATIONS
325	Somatic alterations in brain tumors. Oncology Reports, 2008, , .	1.2	7
326	Genetic ancestry, skin reflectance and pigmentation genotypes in association with serum vitamin D metabolite balance. Hormone Molecular Biology and Clinical Investigation, 2011, 7, 279-293.	0.3	7
327	Genetic Variation in TLR Genes in Ugandan and South African Populations and Comparison with HapMap Data. PLoS ONE, 2012, 7, e47597.	1.1	7
328	Adverse Clinical Outcome Associated With Mutations That Typify African American Colorectal Cancers. Journal of the National Cancer Institute, 2016, 108, djw164.	3.0	7
329	Cigarette smoking and the association with serous ovarian cancer in African American women: African American Cancer Epidemiology Study (AACES). Cancer Causes and Control, 2017, 28, 699-708.	0.8	7
330	Association of Socioeconomic and Geographic Factors With Google Trends for Tanning and Sunscreen. Dermatologic Surgery, 2018, 44, 236-240.	0.4	7
331	Expression of LC3B and FIP200/Atg17 in brain metastases of breast cancer. Journal of Neuro-Oncology, 2018, 140, 237-248.	1.4	7
332	Disparities in the use of stereotactic radiosurgery for the treatment of lung cancer brain metastases: a SEER-Medicare study. Clinical and Experimental Metastasis, 2020, 37, 85-93.	1.7	7
333	Autologous Fat Transfer for Scar Prevention and Remodeling: A Randomized, Blinded, Placebo-controlled Trial. Plastic and Reconstructive Surgery - Global Open, 2020, 8, e2830.	0.3	7
334	Impact of race on care, readmissions, and survival for patients with glioblastoma: an analysis of the National Cancer Database. Neuro-Oncology Advances, 2021, 3, vdab040.	0.4	7
335	Consensus core clinical data elements for meningiomas (v2021.1). Neuro-Oncology, 2022, 24, 683-693.	0.6	7
336	Identifying stage-specific protein subnetworks for colorectal cancer. BMC Proceedings, 2012, 6, S1.	1.8	6
337	Novel approaches to the analysis of family data in genetic epidemiology. Frontiers in Genetics, 2015, 6, 27.	1.1	6
338	Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. Cancer Medicine, 2019, 8, 2503-2513.	1.3	6
339	Racial/ethnic differences in survival for patients with gliosarcoma: an analysis of the National cancer database. Journal of Neuro-Oncology, 2019, 143, 349-357.	1.4	6
340	Brain and central nervous system tumor statistics: access to accurate data for all countries is critical!. Neuro-Oncology, 2019, 21, 291-292.	0.6	6
341	Cardiometabolic comorbidities and epithelial ovarian cancer risk among African-American women in the African-American Cancer Epidemiology Study (AACES). Gynecologic Oncology, 2020, 158, 123-129.	0.6	6
342	The age of adult pilocytic astrocytoma cells. Oncogene, 2021, 40, 2830-2841.	2.6	6

#	Article	IF	CITATIONS
343	Risk groups of laryngeal cancer treated with chemoradiation according to nomogram scores $\hat{a} \in A$ pooled analysis of RTOG 0129 and 0522. Oral Oncology, 2021, 116, 105241.	0.8	6
344	Cross-sectional survey of patients, caregivers, and physicians on diagnosis and treatment of brain metastases. Neuro-Oncology Practice, 2021, 8, 662-673.	1.0	6
345	Racial Differences in Treatment Modalities Among Female Residents of Florida Diagnosed with Epithelial Ovarian Cancer. Journal of Gynecologic Surgery, 2010, 26, 15-22.	0.0	5
346	Capitalizing on Admixture in Genome-Wide Association Studies: A Two-Stage Testing Procedure and Application to Height in African-Americans. Frontiers in Genetics, 2011, 2, .	1.1	5
347	Tubal ligation and ovarian cancer risk in African American women. Cancer Causes and Control, 2017, 28, 1033-1041.	0.8	5
348	Brain tumor biobanking in the precision medicine era: building a high-quality resource for translational research in neuro-oncology. Neuro-Oncology Practice, 2017, 4, 220-228.	1.0	5
349	Ancestry-Adjusted Vitamin D Metabolite Concentrations in Association With Cytochrome P450 3A Polymorphisms. American Journal of Epidemiology, 2018, 187, 754-766.	1.6	5
350	Nuclear-Mitochondrial interactions influence susceptibility to HIV-associated neurocognitive impairment. Mitochondrion, 2019, 46, 247-255.	1.6	5
351	Long-term trends in glioblastoma survival: implications for historical control groups in clinical trials. Neuro-Oncology Practice, 2019, 7, 158-163.	1.0	5
352	Retrospective clinical trial experimentally validates glioblastoma genome-wide pattern of DNA copy-number alterations predictor of survival. APL Bioengineering, 2020, 4, 026106.	3.3	5
353	Association of metabolic syndrome with glioblastoma: a retrospective cohort study and review. Neuro-Oncology Practice, 2020, 7, 541-548.	1.0	5
354	A Descriptive, Longitudinal Study of Quality of Life and Perceived Health Needs in Patients With Head and Neck Cancer. Journal of the Advanced Practitioner in Oncology, 2016, 7, 640-651.	0.2	5
355	Exposure to radon and heavy particulate pollution and incidence of brain tumors. Neuro-Oncology, 2023, 25, 407-417.	0.6	5
356	Susceptibility scoring in family-based association testing. BMC Genetics, 2003, 4, S49.	2.7	4
357	Splitting random forest (SRF) for determining compact sets of genes that distinguish between cancer subtypes. Journal of Clinical Bioinformatics, 2012, 2, 13.	1.2	4
358	Linkage and related analyses of Barrett's esophagus and its associated adenocarcinomas. Molecular Genetics & G	0.6	4
359	A PTPmu Biomarker is Associated with Increased Survival in Gliomas. International Journal of Molecular Sciences, 2019, 20, 2372.	1.8	4
360	The Translocator Protein (TSPO) Genetic Polymorphism A147T Is Associated with Worse Survival in Male Glioblastoma Patients. Cancers, 2021, 13, 4525.	1.7	4

#	Article	IF	CITATIONS
361	Changes in survival of primary central nervous system lymphoma based on a review of national databases over 40 years Journal of Clinical Oncology, 2017, 35, 2040-2040.	0.8	4
362	Somatic alterations in brain tumors. Oncology Reports, 2008, 20, 203-10.	1.2	4
363	Healthy myeloid-derived suppressor cells express the surface ectoenzyme Vanin-2 (VNN2). Molecular Immunology, 2022, 142, 1-10.	1.0	4
364	Epidemiology of Pineoblastoma in the United States, 2000-2017. Neuro-Oncology Practice, 2022, 9, 149-157.	1.0	4
365	A comprehensive epidemiological review of spinal astrocytomas in the United States. Journal of Neurosurgery: Spine, 2021, 34, 303-309.	0.9	4
366	Statistical practice and transparent reporting in the neurosciences: Preclinical motor behavioral experiments. PLoS ONE, 2022, 17, e0265154.	1.1	4
367	Frontiers of Oncology: Biobanking Resources for the 21st Century. Journal of Clinical Bioinformatics, 2011, 1, 13.	1.2	3
368	Adiposity, inflammation, genetic variants and risk of post-menopausal breast cancer findings from a prospective-specimen-collection, retrospective-blinded-evaluation (PRoBE) design approach. SpringerPlus, 2013, 2, 638.	1.2	3
369	Putative Linkage Signals Identified for Breast Cancer in African American Families. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 442-447.	1.1	3
370	Epidemiology of Glioblastoma and Trends in Glioblastoma Survivorship., 2016,, 11-19.		3
371	Association between urbanicity and surgical treatment among patients with primary glioblastoma in the United States. Neuro-Oncology Practice, 2020, 7, 299-305.	1.0	3
372	Proteins inform survival-based differences in patients with glioblastoma. Neuro-Oncology Advances, 2020, 2, vdaa039.	0.4	3
373	Cancer Informatics for Cancer Centers (CI4CC): Building a Community Focused on Sharing Ideas and Best Practices to Improve Cancer Care and Patient Outcomes. JCO Clinical Cancer Informatics, 2020, 4, 108-116.	1.0	3
374	Age of diagnosis in familial Barrett's associated neoplasia. Familial Cancer, 2022, 21, 115-120.	0.9	3
375	European American Stratification in Ovarian Cancer Case Control Data: The Utility of Genome-Wide Data for Inferring Ancestry. PLoS ONE, 2012, 7, e35235.	1.1	3
376	Epidemiology of primary malignant non-osseous spinal tumors in the United States. Spine Journal, 2022, , .	0.6	3
377	Aligning the Central Brain Tumor Registry of the United States (CBTRUS) histology groupings with current definitions. Neuro-Oncology Practice, 2022, 9, 317-327.	1.0	3
378	Treatment Outcomes for Primary Hepatic Angiosarcoma: National Cancer Database Analysis 2004–2014. Current Oncology, 2022, 29, 3637-3646.	0.9	3

#	Article	IF	CITATIONS
379	Analysis of gene × environment interactions in sibships using mixed models. BMC Genetics, 2003, 4, S18.	2.7	2
380	A Call for Consistent Reporting of Regression in Melanoma. Archives of Dermatology, 2012, 148, 1081.	1.7	2
381	ENVE: a novel computational framework characterizes copy-number mutational landscapes in colorectal cancers from African American patients. Genome Medicine, 2015, 7, 69.	3.6	2
382	Ependymoma, NOS and anaplastic ependymoma incidence and survival in the United States varies widely by patient and clinical characteristics, 2000-2016. Neuro-Oncology Practice, 2020, 7, 549-558.	1.0	2
383	Facilitating Cancer Epidemiologic Efforts in Cleveland via Creation of Longitudinal De-Duplicated Patient Data Sets. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 787-795.	1.1	2
384	Sexually dimorphic impact of the iron-regulating gene, HFE, on survival in glioblastoma. Neuro-Oncology Advances, 2020, 2, vdaa001.	0.4	2
385	Data Matching to Support Analysis of Cancer Epidemiology Among Veterans Compared With Non-Veteran Populationsâ€"An Exemplar in Brain Tumors. JCO Clinical Cancer Informatics, 2021, 5, 985-994.	1.0	2
386	Abstract 5705: Mechanisms and therapeutic implications of hypermutation in gliomas. Cancer Research, 2020, 80, 5705-5705.	0.4	2
387	641â€Incidence and risk factors for stroke associated with immune checkpoint inhibitor therapy in cancer patients using real-world clinical data. , 2020, , .		2
388	Admixture effects in the traditional linkage analysis of admixed families. Ethnicity and Disease, 2002, 12, 411-9.	1.0	2
389	Associations of Racial and Ethnic Category, Age, Comorbidities, and Socioeconomic Factors on Concordance to NCCN Guidelines for Patients With High-Risk Biliary Tract Cancers After Surgery. Frontiers in Oncology, 2022, 12, 771688.	1.3	2
390	EPID-12. INCIDENCE AND SURVIVAL TRENDS FOR MEDULLOBLASTOMAS IN THE UNITED STATES FROM 2001 TO 2013. Neuro-Oncology, 2017, 19, vi71-vi71.	0.6	1
391	Adoption of single agent anticancer therapy for advanced hepatocellular carcinoma and impact of facility type, insurance status, and income on survival: Analysis of the national cancer database 2004–2014. Cancer Medicine, 2021, 10, 4397-4404.	1.3	1
392	A Novel Metric for Hospital Quality in Kidney Cancer Surgery: A Veterans Affairs National Health System Validation of Concept. Urology Practice, 2022, 9, 237-245.	0.2	1
393	Maximizing Cancer Dataâ€"The Future of Cancer Is Now. JAMA Oncology, 0, , .	3.4	1
394	EPID-05. A novel, clinically-relevant classification of pediatric CNS tumors for cancer registries using a clustering analysis. Neuro-Oncology, 2022, 24, i47-i47.	0.6	1
395	Quantitative Trait Loci: Methods and Protocols. American Journal of Human Genetics, 2002, 71, 1000.	2.6	0
396	Vimentin in Upper Gastrointestinal Pathologiesâ€"Response. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1890-1890.	1.1	0

#	Article	IF	CITATIONS
397	EPID-04PREVALENCE OF MALIGNANT PRIMARY BRAIN TUMORS IN THE UNITED STATES COMPARED TO OTHER COMMON CANCERS, 2010. Neuro-Oncology, 2015, 17, v78.4-v79.	0.6	0
398	EPID-05. GLOBAL INCIDENCE OF MALIGNANT BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS. Neuro-Oncology, 2016, 18, vi56-vi56.	0.6	0
399	GENE-47. EVALUATING GLIOMA RISK ASSOCIATED WITH EXTENT OF EUROPEAN ADMIXTURE IN AFRICAN-AMERICANS AND LATINOS. Neuro-Oncology, 2017, 19, vi102-vi103.	0.6	0
400	GENE-53. SEX-SPECIFIC GENE AND PATHWAY MODELING OF INHERITED GLIOMA RISK. Neuro-Oncology, 2017, 19, vi104-vi104.	0.6	0
401	CMET-41. LIFETIME LUNG, BREAST, AND SKIN CANCER BRAIN METASTASES INCIDENCE: A REPRODUCIBLE SEER-MEDICARE STUDY. Neuro-Oncology, 2018, 20, vi62-vi62.	0.6	0
402	EPID-15. INCIDENCE PATTERNS OF PRIMARY BRAIN AND OTHER CENTRAL NERVOUS SYSTEM TUMORS IN APPALACHIA. Neuro-Oncology, 2018, 20, vi83-vi83.	0.6	0
403	EPID-22. RACIAL AND ETHNIC DIFFERENCES IN ADULT GLIOMA INCIDENCE AND SURVIVAL IN THE UNITED STATES. Neuro-Oncology, 2018, 20, vi84-vi84.	0.6	0
404	ACTR-03. A FEASIBILITY TRIAL OF THE MODIFIED ATKINS DIET AND BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi11-vi12.	0.6	0
405	EPID-31. EFFICIENT STUDY OF SURGICALLY TREATED MENINGIOMA THROUGH CLINICAL DATA STANDARDIZATION. Neuro-Oncology, 2019, 21, vi81-vi81.	0.6	O
406	IMMU-01. MYELOID-DERIVED SUPPRESSOR CELL HETEROGENEITY DRIVES GLIOBLASTOMA PROGRESSION IN A SEX-DEPENDENT MANNER. Neuro-Oncology, 2019, 21, vi118-vi118.	0.6	0
407	EPID-21. THE NATIONAL SPECTRUM OF NEWLY-DIAGNOSED BRAIN TUMORS IN ADULT PATIENTS VARIES SIGNIFICANTLY BY PATIENT DEMOGRAPHICS. Neuro-Oncology, 2019, 21, vi79-vi79.	0.6	O
408	Geographic and temporal variations in the utilization of stereotactic radiosurgery for treatment of non-small cell lung cancer brain metastases from 2010 to 2015: An analysis of the national cancer database. Interdisciplinary Neurosurgery: Advanced Techniques and Case Management, 2020, 19, 100580.	0.2	0
409	Participation in Health Services/Population Health Research in US Departments of Medicine. American Journal of Medicine, 2020, 133, 1354-1359.	0.6	0
410	The brain metastasis journey: Experience from patient, caregiver, and physician surveys on diagnosis and treatment of brain metastases Journal of Clinical Oncology, 2021, 39, e14004-e14004.	0.8	0
411	OMIC-10. TRANSCRIPTOMIC ANALYSIS REVEALS SEX DIFFERENCES IN PEDIATRIC BRAIN MECHANISMS. Neuro-Oncology, 2021, 23, i39-i39.	0.6	O
412	Human Genetic Variation and its Implication in Understanding "Raceâ€∤ Ethnicity and Admixture. , 2008, , 129-144.		0
413	Elevation of Plasma α-Synuclein Levels Is Diagnostic of Malignant or Invasive Central Nervous System Neoplasms. Blood, 2015, 126, 5597-5597.	0.6	O
414	Abstract 129: Integrated genomic analysis of survival outliers in glioblastoma. , 2016, , .		0

#	Article	IF	CITATIONS
415	Distinct Epigenetic Shift in a Subset of Glioma CpG Island Methylator Phenotype (G-CIMP) During Tumor Recurrence. SSRN Electronic Journal, 0, , .	0.4	0
416	Whole exome sequencing (WES) to define the genomic landscape of young lung cancer patients (pts) Journal of Clinical Oncology, 2018, 36, 12005-12005.	0.8	0
417	The impact of sorafenib on the treatment and survival of advanced hepatocellular carcinoma (HCC): Analysis of the National Cancer Database (NCDB) from 2004 to 2014. Journal of Clinical Oncology, 2019, 37, e15682-e15682.	0.8	0
418	Abstract 869: Leveraging a novel analysis pipeline for outcomes predictions from routine MRIs. , 2020, , .		0
419	EPID-29. CAUSES OF DEATH FOR PRIMARY BRAIN AND CNS TUMOR PATIENTS IN THE UNITED STATES (2001 –)	Tj.ETQq1	10.784314
420	STEM-08. PLATELETS DRIVES GLIOBLASTOMA ONCOGENESIS BY ENHANCING THE GLIOMA STEM CELL PHENOTYPE. Neuro-Oncology, 2020, 22, ii198-ii198.	0.6	0
421	EPID-02. STEREOTACTIC RADIOSURGERY AND CHEMOTHERAPY TREATMENT PATTERNS IN BREAST CANCER BRAIN METASTASES. Neuro-Oncology, 2020, 22, ii78-ii78.	0.6	O
422	STEM-04. PLATELETS DRIVE GLIOBLASTOMA ONCOGENESIS BY ENHANCING THE GLIOMA STEM CELL PHENOTYPE. Neuro-Oncology, 2020, 22, ii197-ii197.	0.6	0
423	Multiscale, multimodal analysis of tumor heterogeneity in IDH1 mutant vs wild-type diffuse gliomas. , 2019, 14, e0219724.		O
424	Multiscale, multimodal analysis of tumor heterogeneity in IDH1 mutant vs wild-type diffuse gliomas., 2019, 14, e0219724.		0
425	Multiscale, multimodal analysis of tumor heterogeneity in IDH1 mutant vs wild-type diffuse gliomas. , 2019, 14, e0219724.		O
426	Multiscale, multimodal analysis of tumor heterogeneity in IDH1 mutant vs wild-type diffuse gliomas., 2019, 14, e0219724.		0
427	Association of Medicaid expansion under the Affordable Care Act and overall survival among children with cancer Journal of Clinical Oncology, 2022, 40, 6507-6507.	0.8	O
428	An update on the overall epidemiology, clinical characteristics, and outcomes from the COVID-19 and Cancer Consortium (CCC19) Journal of Clinical Oncology, 2022, 40, 10565-10565.	0.8	0